Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer

International Journal of Biological Markers

Volumn 11, Issue 1, 1996, Pages 29-35

  Robertson, J F R ^a   Cannon, P M ^a   Nicholson, R I ^b   Blamey, R W ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b Tenovus Inst for Cancer Research   (United Kingdom)

Author keywords

Breast cancer; Oestrogen receptor; Progesterone receptor; Prognostic variables

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; PROGNOSIS; SURVIVAL TIME; TUMOR GROWTH;

EID: 0029870691     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089601100106     Document Type: Article

References (37)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet 1896; ii: 104-7.
2. Toft G, Gorski J. A receptor molecule for oestrogens: isolation from the rat uterus and preliminary characterisation. Proc Natl Acad Sci USA 1966; 55: 1574-81.
3. Jensen EV, Block GE, Smith S, Kyser K, DeSombre ER. Estrogen receptors and breast cancer response to adrenalectomy. Natl Inst Cancer Monograph 1971; 34: 55-70.
4. McGuire WL, Garbone PP, Sears ME, Escher GC. Estrogen receptors in human breast cancer: an overview. McGuire, Carbone, Vollmer, eds. New York: Raven Press, 1975; 1-7.
5. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS. Progesterone receptors as prognostic factors in stage II breast cancer. NEJM 1983; 309, 22: 1343-7.
6. Pichon MF, Palud C, Brunet M, Milgrom ER. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer 1980; 40: 3357-60.
7. Mason BH, Holdaway IM, Nullins PR, Yeb LH, Kay RG. Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Research 1983; 43: 2985-90.
8. Howell A, Harland RNL, Bramwell VHC, et al. Steroid hormone receptors and survival after first relapse in breast cancer. Lancet 1984; i: 588-91.
9. Hawkins RA, White G, Bundred NJ, et al. Prognostic significance of oestrogen and progesterone receptor activities in breast cancer. Br J Surg 1987; 74: 1009-13.
10. Sutton R, Campbell M, Cooke T, Nicholson R, Griffiths K, Taylor I. Predictive power of progesterone receptor in early breast cancer. Br J Surg 1987; 74: 223-6.
11. McGuire WL, Horwitz KB, Pearson M, Segaloff A. Current status of oestrogen and progesterone receptors in breast cancer. Cancer 1977; 39: 2934-47.
12. Brooks SC, Saunders E, Singhakowinta A, Vaitkevicius VK. Relation of tumour content of estrogen and progesterone receptors with response of patient to endocrine therapy. Cancer 1980; 46: 2775-8.
13. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46: 2884-8.
14. Ravdin PM, Green S, Door TM, et al. Prognostic significance of progesterone receptor levels in estrogen positive patients with metastatic breast cancer treated with Ta-moxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992; 10: 1284-91.
15. Hayward JL, Carborne PP, Heuston JC, Kumaoka S, Rubens RD. Assessment of response to therapy in advanced breast cancer. Cancer 1977; 39: 1289-93.
16. British Breast Group. Assessment of response to treatment in advanced breast cancer. Lancet 1972; ii: 38-9.
17. Lee ET, Desu MM. A computer program for comparing K samples with right censored data. Computer Programmes Biomed 1972; 2: 315-21. Br J Surg 1991; 78: 591-4.
18. Lee ET, Desu MM. A computer program for comparing K samples with right censored data. Computer Programmes Biomed 1972; 2: 315-21. Br J Surg 1991; 78: 591-4.
19. Jensen EW. Hormone dependency of breast cancer. Cancer 1981; 47: 2319-26.
20. Stewart JF, King R, Hayward JL, Rubens RD. Estrogen and progesterone receptors: correlation of response rates, site and timing of receptor analysis. Breast Cancer Res Treatment 1982; 2: 243-50.
21. Williams MR, Todd JH, Ellis IO, et al. Oestrogen receptor in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer 1987; 5: 67-73.
22. Stewart JF, King RJB, Sexton SA, Millis RR, Rubens RD, Hayward JL. Oestrogen receptors, site of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 1981; 17: 449-53.
23. Howat JMT, Harris M, Swindell R, Barnes DM. The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer 1985; 51: 263-70.
24. Williams MR, Gilson D, Marsh L, et al. The early results from a randomised study of radiotherapy versus Tamoxifen as initial treatment for stage III breast cancer. Eur J Surg Oncol 1988; 14: 235-40.
25. Robertson JFR, Todd JH, Ellis IO, Elston CW, Blarney RW. Comparison of mastectomy with Tamoxifen for treating elderly patients with operable breast cancer. Br Med J 1988; 297: 511-4.
26. Bates T, Riley DL, Houghton J, Fallowfield L, Baum M. Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with Tamoxifen and optimal surgery with Tamoxifen alone. Br J Surg 1991; 78: 591-4.
27. Horwitz KB, McGuire WL, Pearson OH, Segaloff A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975; 189: 726-7.
28. McGuire WL. Hormone receptors: Their role in predicting prognosis and response to endocrine therapy. Sem Oncol 1978; 5: 428-33.
29. Johnson PA, Bonomi PD, Anderson KM, et al. Progesterone receptor as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study. Cancer Treatment Reports 1983; 67: 717-20.
30. Brocklehurst D, Wilde CE, Finbow JAH, Brett R, Champion AE, Dewhurst DG. Relative importance of oestrogen and progesterone receptor assays as prognostic indicators in primary breast cancer: a short-term study. Clin Chem 1989; 35, 2: 238-40.
31. Collett K, Skjaerven R, Thorsen T, Hartveit F, Maehle BO. The prognostic role of progesterone receptor status and age in relation to axillary node status in breast cancer patients. Eur J Cancer 1989; 25: 959-64.
32. Vollenweider L, Barrelet L, Wong Y, Lemarchand-Beraud T, Gomez F. The predictive value of oestrogen and progesterone receptor concentrations on the clinical behaviour of breast cancer in women: clinical correlation on 547 patients. Cancer 1986; 57: 1171-80.
33. Galea MH, Blarney RW, Elston CW, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992; 22: 207-19.
34. Williams MR, Todd JH, Nicholson RI, Elston CW, Blamey RW, Griffiths K. Survival patterns in hormone treated advanced breast cancer. Br J Surg 1986; 73: 752-5.
35. Robertson JFR, Dixon AC, Nicholson RI, Ellis IO, Elston CW, Blarney RW. Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treatment 1992; 22: 221-7.
36. Brenner SE, Clarke GM, McGuire WL. Review: steroid receptors, cellular kinetics and lymph node status as prognostic factors in breast cancer. Am J Med Sciences 1988; 296: 59-66.
37. Hawkins RA. Receptors in the management of breast cancer. Br J Hosp Med 1985; 34: 160-4.